| Ticker Details |
Spero Therapeutics, Inc.
Spero Therapeutics Inc is a multi asset clinical stage biopharmaceutical company. It is focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections.
|
| IPO Date: |
November 2, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$71.05M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.25 | 3.57%
|
| Avg Daily Range (30 D): |
$0.07 | 4.34%
|
| Avg Daily Range (90 D): |
$0.09 | 3.88%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.6M |
| Avg Daily Volume (30 D): |
1.6M |
| Avg Daily Volume (90 D): |
1.15M |
| Trade Size |
| Avg Trade Size (Sh.): |
248 |
| Avg Trade Size (Sh.) (30 D): |
296 |
| Avg Trade Size (Sh.) (90 D): |
226 |
| Institutional Trades |
| Total Institutional Trades: |
102 |
| Avg Institutional Trade: |
$1.63M |
| Avg Institutional Trade (30 D): |
$.51M |
| Avg Institutional Trade (90 D): |
$.57M |
| Avg Institutional Trade Volume: |
.2M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.87M |
| Avg Closing Trade (30 D): |
$.74M |
| Avg Closing Trade (90 D): |
$.62M |
| Avg Closing Volume: |
298.86K |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$.14
|
$-.16
|
$-.13
|
|
Diluted EPS
|
$.14
|
$-.16
|
$-.13
|
|
Revenue
|
$47M
|
$M
|
$.26M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$7.38M
|
$-9.55M
|
$-7.2M
|
|
Operating Income / Loss
|
$6.03M
|
$-9.93M
|
$-7.54M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$19.58M
|
$-5.36M
|
$15.86M
|
|
PE Ratio
|
|
|
|
|
|
|
